VIVOS THERAPEUTICS INC (VVOS)
US92859E2072 - Common Stock
Taking everything into account, VVOS scores 3 out of 10 in our fundamental rating. VVOS was compared to 118 industry peers in the Health Care Providers & Services industry. While VVOS seems to be doing ok healthwise, there are quite some concerns on its profitability. VVOS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
VVOS had negative earnings in the past year.
VVOS had a negative operating cash flow in the past year.
In the past 5 years VVOS always reported negative net income.
In the past 5 years VVOS always reported negative operating cash flow.
1.2 Ratios
VVOS has a worse Return On Assets (-126.55%) than 94.02% of its industry peers.
VVOS has a Return On Equity of -3303.89%. This is amonst the worse of the industry: VVOS underperforms 83.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -126.55% | ||
| ROE | -3303.89% | ||
| ROIC | N/A |
ROA(3y)-120.22%
ROA(5y)-110.13%
ROE(3y)-1293.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VVOS's Gross Margin of 59.95% is amongst the best of the industry. VVOS outperforms 82.91% of its industry peers.
In the last couple of years the Gross Margin of VVOS has declined.
VVOS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 59.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.05%
GM growth 5Y-3.47%
2. Health
2.1 Basic Checks
VVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VVOS has been increased compared to 1 year ago.
VVOS has more shares outstanding than it did 5 years ago.
VVOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
VVOS has an Altman-Z score of -16.34. This is a bad value and indicates that VVOS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -16.34, VVOS is not doing good in the industry: 87.18% of the companies in the same industry are doing better.
VVOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.34 |
ROIC/WACCN/A
WACC9%
2.3 Liquidity
VVOS has a Current Ratio of 0.34. This is a bad value and indicates that VVOS is not financially healthy enough and could expect problems in meeting its short term obligations.
VVOS's Current ratio of 0.34 is on the low side compared to the rest of the industry. VVOS is outperformed by 92.31% of its industry peers.
VVOS has a Quick Ratio of 0.34. This is a bad value and indicates that VVOS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of VVOS (0.34) is worse than 91.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.34 |
3. Growth
3.1 Past
VVOS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.62%, which is quite impressive.
Looking at the last year, VVOS shows a very negative growth in Revenue. The Revenue has decreased by -13.81% in the last year.
Measured over the past years, VVOS shows a very strong growth in Revenue. The Revenue has been growing by 29.50% on average per year.
EPS 1Y (TTM)45.62%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q39%
Revenue 1Y (TTM)-13.81%
Revenue growth 3Y1.83%
Revenue growth 5Y29.5%
Revenue growth Q2Q-17.77%
3.2 Future
The Earnings Per Share is expected to grow by 36.38% on average over the next years. This is a very strong growth
Based on estimates for the next years, VVOS will show a quite strong growth in Revenue. The Revenue will grow by 17.23% on average per year.
EPS Next Y68.24%
EPS Next 2Y36.38%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year23.36%
Revenue Next 2Y17.23%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
VVOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VVOS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VVOS's earnings are expected to grow with 36.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.38%
EPS Next 3YN/A
5. Dividend
5.1 Amount
VVOS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIVOS THERAPEUTICS INC
NASDAQ:VVOS (5/16/2024, 3:30:02 PM)
After market: 2.2 -0.06 (-2.65%)2.26
+0.08 (+3.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.73M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -126.55% | ||
| ROE | -3303.89% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 59.95% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.34 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)45.62%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y68.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-13.81%
Revenue growth 3Y1.83%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y